Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
  • A61K47/6817—Toxins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
  • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
  • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/475—Growth factors; Growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/77—Internalization into the cell
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

• the present invention relates to the field of therapeutic proteins, and in particular, to the field of therapeutic proteins that are capable of inactivating, blocking, attenuating, eliminating and/or reducing the concentration of one or more target molecules in vitro or in vivo.
• Therapeutic treatments often require the inactivation or blocking of one or more target molecules that act on or in the vicinity of a cell.
• antibody-based therapeutics often function by binding to a particular antigen expressed on the surface of a cell, or to a soluble ligand, thereby interfering with the antigen's normal biological activity.
• Antibodies and other binding constructs directed against various cytokines e.g. , IL-1 , IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, etc.
• cytokines e.g. , IL-1 , IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, etc.
• Therapeutic agents of this type typically function by blocking the interaction between the cytokine and its receptor in order to attenuate or inhibit cellular signaling. In certain contexts, however, it would be therapeutically beneficial to inactivate or inhibit the activity of a target molecule in a manner that does not necessarily involve blocking its physical interaction with another component.
• One way in which such non- blocking attenuation of a target molecule could be achieved would be to reduce the extracellular or cell surface concentration of the target molecule.
• genetic and nucleic acid-based strategies for reducing the amount or concentration of a given target molecule are known in the art, such strategies are often fraught with substantial technical complications and unintended side effects in therapeutic settings. Accordingly, alternative non-blocking strategies are needed to facilitate the inactivation or attenuation of various target molecules for therapeutic purposes.
• the present invention is based, at least in part, on the concept of attenuating or inactivating a target molecule by facilitating or bringing about a physical linkage between the target molecule and an internalizing effector protein.
• the target molecule can be forced to be internalized into the cell along with the internalizing effector protein, and processed by the intracellular degradative machinery, or otherwise attenuated, sequestered, or inactivated.
• This mechanism represents a novel and inventive strategy for inactivating or attenuating the activity of a target molecule without necessarily blocking the interaction between the target molecule and its binding partners.
• the present invention provides a multispecific antigen-binding molecule that is capable of simultaneously binding a target molecule (T) and an internalizing effector protein (E). More specifically, the present invention provides a multispecific antigen-binding molecule comprising a first antigen-binding domain (D1 ), and a second antigen-binding domain (D2), wherein D1 specifically binds T, and D2 specifically binds E, and wherein the
• simultaneous binding of T and E by the multispecific antigen-binding molecule attenuates the activity of T to a greater extent than the binding of T by D1 alone.
• the enhanced attenuation of the activity of T may be due to the forced internalization/degradation of T through its physical linkage to E; however, other mechanisms of action are possible and are not excluded from the scope of the present invention.
• the present invention provides methods of using the multispecific antigen- binding molecule to inactivate or attenuate the activity of a target molecule (T).
• T target molecule
• the present invention provides a method for inactivating or attenuating the activity of T by contacting T and an internalizing effector protein (E) with a multispecific antigen-binding molecule, wherein the multispecific antigen-binding molecule comprises a first antigen-binding domain (D1 ) and a second antigen-binding domain (D2), wherein D1 specifically binds T, and wherein D2 specifically binds E; and wherein the simultaneous binding of T and E by the multispecific antigen-binding molecule attenuates the activity of T to a greater extent than the binding of T by D1 alone.
• D1 first antigen-binding domain
• D2 second antigen-binding domain
• D1 and/or D2 comprise(s) at least one antibody variable region.
• the multispecific antigen-binding molecule can, in some embodiments, be a bispecific antibody, wherein D1 comprises an antibody heavy and light chain variable region (HCVR/LCVR) pair that specifically binds T, and wherein D2 comprises an HCVR/LCVR pair that specifically binds E.
• D1 and/or D2 may comprise a peptide or polypeptide that specifically interacts with the target molecule (T) and/or the internalizing effector protein (E).
• D1 may comprise a portion of a ligand that specifically binds the cell surface receptor target molecule.
• D2 may comprise a portion of a ligand that specifically binds the cell surface internalizing receptor.
• D1 comprises an antibody variable region that specifically binds T
• D2 comprises a peptide or polypeptide that specifically binds E.
• D1 comprises a peptide or polypeptide that specifically binds T
• D2 comprises an antibody variable region that specifically binds E.
• the end result is that T and E are capable of being physically linked, directly or indirectly, via the simultaneous binding of T and E by a multispecific antigen-binding molecule.
• D1 is a first antigen-binding domain
• D2 is a second antigen binding domain
• T is a target molecule
• E is an internalizing effector protein
• R is a receptor which internalizes upon binding E.
• Panel A depicts the situation in which both T and E are membrane-associated.
• Panel B depicts the situation in which T is soluble and E is membrane- associated.
• Panel C depicts the situation in which T is membrane-associated and E is a soluble protein that interacts with, and is internalized into the cell via the interaction of E and R.
• Panel D depicts the situation in which T is soluble and E is a soluble protein that interacts with, and is internalized into the cell via the interaction of E and R.
• Figure 2 shows the results of an immunoprecipitation experiment performed on two different cells (Cell-1 expressing FcyR1 alone, and Cell-2 expressing Krm2 and FcyR1 ) following incubation for different amounts of time (0, 15, 30 and 60 minutes) with a DKK1-mFc multispecific antigen-binding molecule.
• Figure 3 shows the relative IL-4-induced luminescence produced by Stat6-luc reporter HEK293 cells in the presence and absence of an anti-IL-4R/anti-CD63 multispecific antigen binding protein ("ab conjugate") or control constructs ("control 1 " and "control 2") at various concentrations of IL-4.
• FIG 4 shows the results of an experiment carried out in the same manner as the experiment shown in Figure 3, except that CD63 expression was significantly reduced in the reporter cell line by an siRNA directed against CD63.
• Figure 5 shows the results of an experiment carried out in a similar manner as the experiments shown in Figures 3 and 4, except that the reporter cells were incubated with the multispecific antigen binding protein ("Ab conjugate") or control constructs ("control 1 " and “control 2") for 2 hours or overnight prior to the addition of IL-4 ligand.
• the top row of bar graphs represent the results of experiments conducted in cells expressing normal levels of CD63 ("untransfected"), while the bottom row of bar graphs represents the results of experiments conducted in cells in which CD63 expression was significantly reduced in the reporter cell line by a n siRNA directed against CD63.
• Figure 6 shows the results of an experiment carried out in a similar manner as the experiments shown in Figures 3 and 4, except that the reporter cells were incubated with the anti-IL-4R/anti-CD63 multispecific antigen binding protein ("Ab conjugate") or control constructs ("control 1" and "control 2") for 15 minutes, 30 minutes, 1 hour or 2 hours prior to the addition of IL-4 ligand.
• Ab conjugate anti-IL-4R/anti-CD63 multispecific antigen binding protein
• control constructs control 1 and "control 2”
• FIG. 7 shows the results of an experiment in which Stat6-luc reporter cells were treated with 10 pM IL-4 in the presence of various dilutions of an anti-IL-4R x anti-CD63 bispecific antibody ("bispecific"), or control constructs (anti-IL-4R monospecific, or mock bispecific that only binds IL-4R).
• bispecific an anti-IL-4R x anti-CD63 bispecific antibody
• control constructs anti-IL-4R monospecific, or mock bispecific that only binds IL-4R
• Figure 8 shows the results of experiments in which HEK293 cells were treated with a SOST construct labeled with a myc tag and a pH-sensitive label (that produces a fluorescent signal at low pH), along with the various mono-specific and bispecific antibodies as shown. Results are expressed in terms of number of fluorescent spots (i.e., labeled vesicles) per cell.
• Panel A shows the results following incubation on ice for 3 hours
• panel B shows the results following 1 hour incubation at 37°C
• panel C shows the results following 3 hours incubation at 37°C.
• Figure 9 shows the results of experiments in which HEK293 cells were treated with fluorescently-labeled lipopolysaccharide (LPS) from E. coli (Panel A) or S. minnesota (Panel B), along with an anti-CD63 x anti-LPS bispecific antibody, control antibodies, or LPS only, for various times, followed by quenching of non-internalized (i.e., surface bound) fluorophore. Fluorescent signal therefore reflects internalized LPS under the various conditions shown. Results are expressed in terms of number of fluorescent spots (i.e., labeled vesicles) per cell.
• LPS fluorescently-labeled lipopolysaccharide
• a target molecule's activity can be attenuated by linking the target molecule to an internalizing effector protein via a
• the present invention provides multispecific antigen binding molecules comprising a first antigen-binding domain (also referred to herein as "D1 "), and a second antigen-binding domain (also referred to herein as “D2").
• D1 and D2 each bind different molecules.
• D1 specifically binds a "target molecule”.
• the target molecule is also referred to herein as "T”.
• D2 specifically binds an "internalizing effector protein”.
• the internalizing effector protein is also referred to herein as "E”.
• the simultaneous binding of T and E by the multispecific antigen-binding molecule attenuates the activity of T to a greater extent than the binding of T by D1 alone.
• the expression "simultaneous binding,” in the context of a multispecific antigen-binding molecule means that the multispecific antigen-binding molecule is capable of contacting both a target molecule (T) and an
• binding of the multispecific antigen-binding molecule to the T and E components may be sequential; e.g., the multispecific antigen-binding molecule may first bind T and then bind E, or it may first bind E first and then bind T. In any event, so long as T and E are both bound by the multispecific antigen-binding molecule for some period of time (regardless of the sequential order of binding), the
• multispecific antigen-binding molecule will be deemed to "simultaneously bind" T and E for purposes of the present disclosure. Without being bound by theory, the enhanced inactivation of T is believed to be caused by the internalization and degradative rerouting of T within a cell due to its physical linkage to E.
• the multispecific antigen-binding molecules of the present invention are thus useful for inactivating and/or reducing the activity and/or extracellular concentration of a target molecule without directly blocking or antagonizing the function of the target molecule.
• a multispecific antigen-binding molecule can be a single multifunctional polypeptide, or it can be a multimeric complex of two or more polypeptides that are covalently or non-covalently associated with one another.
• any antigen binding construct which has the ability to simultaneously bind a T and an E molecule is regarded as a multispecific antigen-binding molecule.
• Any of the multispecific antigen-binding molecules of the invention, or variants thereof, may be constructed using standard molecular biological techniques (e.g., recombinant DNA and protein expression technology), as will be known to a person of ordinary skill in the art.
• the multispecific antigen-binding molecules of the present invention comprise at least two separate antigen-binding domains (D1 and D2).
• the expression "antigen- binding domain” means any peptide, polypeptide, nucleic acid molecule, scaffold-type molecule, peptide display molecule, or polypeptide-containing construct that is capable of specifically binding a particular antigen of interest.
• the term “specifically binds” or the like, as used herein, means that the antigen-binding domain forms a complex with a particular antigen characterized by a dissociation constant (K D ) of 500 pM or less, and does not bind other unrelated antigens under ordinary test conditions.
• K D dissociation constant
• Unrelated antigens are proteins, peptides or polypeptides that have less than 95% amino acid identity to one another.
• antigen-binding domains that can be used in the context of the present invention include antibodies, antigen-binding portions of antibodies, peptides that specifically interact with a particular antigen (e.g., peptibodies), receptor molecules that specifically interact with a particular antigen, proteins comprising a ligand-binding portion of a receptor that specifically binds a particular antigen, antigen-binding scaffolds (e.g., DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, and other scaffolds based on naturally occurring repeat proteins, etc., [see, e.g., Boersma and Pluckthun, 201 1 , Curr. Opin. Biotechnol. 22:849-857, and references cited therein]), and aptamers or portions thereof.
• a particular antigen e.g., peptibodies
• receptor molecules that specifically interact with a particular antigen
• proteins comprising a ligand-bind
• an "antigen-binding domain,” for purposes of the present invention may comprise or consist of a ligand or portion of a ligand that is specific for the receptor.
• the D1 component of the multispecific antigen- binding molecule may comprise the I L-4 ligand or a portion of the I L-4 ligand that is capable of specifically interacting with I L-4R; or if the internalizing effector protein (E) is transferrin receptor, the D2 component of the multispecific antigen-binding molecule may comprise transferrin or a portion of transferrin that is capable of specifically interacting with the transferrin receptor.
• an "antigen-binding domain,” for purposes of the present invention may comprise or consist of the receptor or a ligand-binding portion of the receptor.
• the D1 component of the multispecific antigen-binding molecule may comprise the ligand-binding domain of the IL-6 receptor; or if the internalizing effector protein (E) is an indirectly internalized protein (as that term is defined elsewhere herein), the D2 component of the multispecific antigen-binding molecule may comprise a ligand-binding domain of a receptor specific for E.
• an antigen-binding domain includes polypeptides that bind a particular antigen (e.g.
• K D means the equilibrium dissociation constant of a particular protein-protein interaction (e.g., antibody-antigen interaction). Unless indicated otherwise, the K D values disclosed herein refer to K D values determined by surface plasmon resonance assay at 25°C.
• an "antigen-binding domain” can comprise or consist of an antibody or antigen-binding fragment of an antibody.
• antibody means any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., T or E).
• CDR complementarity determining region
• antibody includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof [e.g., IgM).
• Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or V H ) and a heavy chain constant region.
• the heavy chain constant region comprises three domains, C H 1 , C H 2 and C H 3.
• Each light chain comprises a light chain variable region (abbreviated herein as LCVR or V L ) and a light chain constant region.
• the light chain constant region comprises one domain (Q_1 ).
• the V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
• CDRs complementarity determining regions
• Each V H and V L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
• the FRs of the antibodies of the invention may be identical to the human germline sequences, or may be naturally or artificially modified.
• An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
• the D1 and/or D2 components of the multispecific antigen-binding molecules of the present invention may comprise or consist of antigen-binding fragments of full antibody molecules.
• antigen-binding portion of an antibody, "antigen-binding fragment” of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex.
• Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains.
• DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized.
• the DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
• Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g. , an isolated complementarity determining region (CD ) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide.
• CD isolated complementarity determining region
• engineered molecules such as domain-specific antibodies, single domain antibodies, domain- deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMI Ps), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.
• SMI Ps small modular immunopharmaceuticals
• shark variable IgNAR domains are also encompassed within the expression "antigen-binding fragment," as used herein.
• An antigen-binding fragment of an antibody will typically comprise at least one variable domain.
• the variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences.
• _ domains may be situated relative to one another in any suitable arrangement.
• the variable region may be dimeric and contain V H -V H , V H -V L or V L -V L dimers.
• the antigen-binding fragment of an antibody may contain a monomeric V H or V L domain.
• an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain.
• variable and constant domains that may be found within an antigen- binding fragment of an antibody of the present invention include: (i) V H -C H 1 ; (ii) V H -C H 2; (iii) V H - C H 3; (iv) V H -C H 1 -C H 2; (v) V H -CH1-C h 2-CH3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1 ; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1 -C H 2; (xii) V L -C h 1-C h 2-CH3; (xiii) V L -C H 2-C H 3
• variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region.
• a hinge region may consist of at least 2 (e.g. , 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule.
• an antigen-binding fragment may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V H or V L domain (e.g., by disulfide bond(s)).
• the multispecific antigen-binding molecules of the present invention may comprise or consist of human antibodies and/or recombinant human antibodies, or fragments thereof.
• human antibody includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies may nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3.
• the term "human antibody”, as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
• the multispecific antigen-binding molecules of the present invention may comprise or consist of recombinant human antibodies or antigen-binding fragments thereof.
• recombinant human antibody as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res.
• Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V H and V L regions of the recombinant antibodies are sequences that, while derived from and related to human germline V H and V L sequences, may not naturally exist within the human antibody germline repertoire in vivo.
• the multispecific antigen-binding molecules of the invention are bispecific antibodies; e.g., bispecific antibodies comprising an antigen-binding arm that specifically binds a target molecule (T) and an antigen-binding arm that specifically binds an internalizing effector protein (E).
• T target molecule
• E internalizing effector protein
• Exemplary bispecific formats that can be used in the context of the present invention include, without limitation, e.g., scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-lg, Quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes, etc.), CrossMab, CrossFab, (SEED)body, leucine zipper, Duobody, lgG1/lgG2, dual acting Fab (DAF)-lgG, and Mab 2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-1 1 , and references cited therein, for a review of the foregoing formats).
• the multispecific antigen-binding molecules of the present invention may also comprise one or more multimerizing component(s).
• the multimerizing components can function to maintain the association between the antigen-binding domains (D1 and D2).
• a "multimerizing component” is any macromolecule, protein, polypeptide, peptide, or amino acid that has the ability to associate with a second multimerizing component of the same or similar structure or constitution.
• a multimerizing component may be a polypeptide comprising an immunoglobulin C H 3 domain.
• a non-limiting example of a multimerizing component is an Fc portion of an immunoglobulin, e.g., an Fc domain of an IgG selected from the isotypes lgG1 , lgG2, lgG3, and lgG4, as well as any allotype within each isotype group.
• the multimerizing component is an Fc fragment or an amino acid sequence of 1 to about 200 amino acids in length containing at least one cysteine residues.
• the multimerizing component is a cysteine residue, or a short cysteine-containing peptide.
• Other multimerizing domains include peptides or polypeptides comprising or consisting of a leucine zipper, a helix-loop motif, or a coiled-coil motif.
• the multispecific antigen-binding molecules of the present invention comprise two multimerizing domains, M1 and M2, wherein D1 is attached to M1 and D2 is attached to M2, and wherein the association of M1 with M2 facilitates the physical linkage of D1 and D2 to one another in a single multispecific antigen-binding molecule.
• M1 and M2 are identical to one another.
• M1 can be an Fc domain having a particular amino acid sequence
• M2 is an Fc domain with the same amino acid sequence as M1.
• M1 and M2 may differ from one another at one or more amino acid position.
• M1 may comprise a first immunoglobulin (Ig) C H 3 domain and M2 may comprise a second Ig C H 3 domain, wherein the first and second Ig C H 3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the targeting construct to Protein A as compared to a reference construct having identical M1 and M2 sequences.
• the Ig C H 3 domain of M1 binds Protein A and the Ig C H 3 domain of M2 contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering).
• the CH3 of M2 may further comprise a Y96F modification (by IMGT; Y436F by EU).
• modifications that may be found within the C H 3 of M2 include: D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the case of an lgG1 Fc domain; N44S, K52N, and V82I (IMGT; N384S, K392N, and V422I by EU) in the case of an lgG2 Fc domain; and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU) in the case of an lgG4 Fc domain.
• the D2 component of the multispecific antigen- binding molecule specifically binds an internalizing effector protein ("E").
• An internalizing effector protein is a protein that is capable of being internalized into a cell or that otherwise participates in or contributes to retrograde membrane trafficking.
• the internalizing effector protein is a protein that undergoes transcytosis; that is, the protein is internalized on one side of a cell and transported to the other side of the cell (e.g., apical-to- basal).
• the internalizing effector protein is a cell surface-expressed protein or a soluble extracellular protein.
• the present invention also contemplates embodiments in which the internalizing effector protein is expressed within an intracellular compartment such as the endosome, endoplasmic reticulum, Golgi, lysosome, etc.
• an intracellular compartment such as the endosome, endoplasmic reticulum, Golgi, lysosome, etc.
• proteins involved in retrograde membrane trafficking e.g., pathways from
• internalizing effector proteins may serve as internalizing effector proteins in various embodiments of the present invention.
• the binding of D2 to an internalizing effector protein causes the entire multispecific antigen-binding molecule, and any molecules associated therewith (e.g., a target molecule bound by D1 ), to also become internalized into the cell.
• internalizing effector proteins include proteins that are directly internalized into a cell, as well as proteins that are indirectly internalized into a cell.
• membrane-associated molecules with at least one extracellular domain e.g., transmembrane proteins, GPI-anchored proteins, etc.
• internalizing effector proteins that are directly internalized into a cell include, e.g., CD63, MHC-I (e.g., HLA-B27), Kremen-1 , Kremen-2, L P5, LRP6, LRP8, transferrin receptor, LDL-receptor, LDL-related protein 1 receptor, ASGR1 , ASGR2, amyloid precursor protein-like protein-2 (APLP2), apelin receptor (APLNR), MAL (Myelin And Lymphocyte protein, a.k.a.
• VIP17 IGF2R, vacuolar-type H + ATPase, diphtheria toxin receptor, folate receptor, glutamate receptors, glutathione receptor, leptin receptors, scavenger receptors (e.g., SCARA1-5, SCARB1-3, CD36), etc.
• the D2 component of the multispecific antigen-binding molecule can be, e.g., an antibody or antigen-binding fragment of an antibody that specifically binds E, or a ligand or portion of a ligand that specifically interacts with the effector protein.
• the D2 component can comprise or consist of a Kremen ligand (e.g., DKK1 ) or Kremen-binding portion thereof.
• the D2 component can comprise or consist of a ligand specific for the receptor (e.g., asialoorosomucoid [ASOR] or Beta-GalNAc) or a receptor-binding portion thereof.
• a ligand specific for the receptor e.g., asialoorosomucoid [ASOR] or Beta-GalNAc
• Internalizing effector proteins that are indirectly internalized into a cell include proteins and polypeptides that do not internalize on their own, but become internalized into a cell after binding to or otherwise associating with a second protein or polypeptide that is directly internalized into the cell.
• Proteins that are indirectly internalized into a cell include, e.g., soluble ligands that are capable of binding to an internalizing cell surface-expressed receptor molecule.
• a non-limiting example of a soluble ligand that is (indirectly) internalized into a cell via its interaction with an internalizing cell surface-expressed receptor molecule is transferrin.
• E transferrin (or another indirectly internalized protein)
• the binding of D2 to E, and the interaction of E with transferrin receptor causes the entire multispecific antigen-binding molecule, and any molecules associated therewith (e.g. , a target molecule bound by D1 ), to become internalized into the cell concurrent with the internalization of E and its binding partner.
• the D2 component of the multispecific antigen-binding molecule can be, e.g., an antibody or antigen-binding fragment of an antibody that specifically binds E, or a receptor or portion of a receptor that specifically interacts with the soluble effector protein.
• E is an indirectly internalized effector protein
• the D2 component can comprise or consist of the corresponding cytokine receptor or ligand-binding portion thereof.
• the D1 component of the multispecific antigen- binding molecule specifically binds a target molecule ("T").
• a target molecule is any protein, polypeptide, or other macromolecule whose activity or extracellular concentration is desired to be attenuated, reduced or eliminated.
• the target molecule to which D1 binds is a protein or polypeptide [i.e. , a "target protein”]; however, the present invention also includes embodiments wherein the target molecule (“T”) is a carbohydrate, glycoprotein, lipid, lipoprotein, lipopolysaccharide, or other non-protein polymer or molecule to which D1 binds.
• T can be a cell surface-expressed target protein or a soluble target protein.
• Target binding by the multispecific antigen-binding molecule may take place in an extracellular or cell surface context. In certain embodiments, however, the multispecific antigen- binding molecule binds a target molecule inside the cell, for example within an intracellular component such as the endoplasmic reticulum, Golgi, endosome, lysosome, etc.
• cell surface-expressed target molecules include cell surface-expressed receptors, membrane-bound ligands, ion channels, and any other monomeric or multimeric polypeptide component with an extracellular portion that is attached to or associated with a cell membrane.
• Non-limiting, exemplary cell surface-expressed target molecules that may be targeted by the multispecific antigen-binding molecule of the present invention include, e.g., cytokine receptors (e.g., receptors for I L-1 , I L-4, IL-6, IL-13, I L-22, I L-25, IL-33, etc.), as well as cell surface targets including other type 1 transmembrane receptors such as PRLR, G-protein coupled receptors such as GCGR, ion channels such as Nav1 .7, ASIC1 or ASIC2, non-receptor surface proteins such as MHC-I (e.g., HLA-B * 27), etc.
• cytokine receptors e.g., receptors for I L-1 , I L-4, IL-6, IL-13, I L-22, I L-25, IL-33, etc.
• cell surface targets including other type 1 transmembrane receptors such as PRLR, G-protein coupled receptors such as GCGR, i
• the D1 component of the multispecific antigen-binding molecule can be, e.g., an antibody or antigen- binding fragment of an antibody that specifically binds T, or a ligand or portion of a ligand that specifically interacts with the cell surface-expressed target protein.
• the D1 component can comprise or consist of IL-4 or a receptor-binding portion thereof.
• soluble target molecules include cytokines, growth factors, and other ligands and signaling proteins.
• Non-limiting exemplary soluble target protein that may be targeted by the multispecific antigen-binding molecule of the present invention include, e.g., IL- 1 , IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, SOST, DKK1 , etc.
• Soluble targets molecules also include, e.g., non-human target molecules such as allergens (e.g., Fel D1 , Betvl , CryJ1 ), pathogens (e.g., Candida albicans, S. aureus, etc.), and pathogenic molecules (e.g.,
• the D1 component of the multispecific antigen-binding molecule can be, e.g., an antibody or antigen-binding fragment of an antibody that specifically binds T, or a receptor or portion of a receptor that specifically interacts with the soluble target molecule.
• the D1 component can comprise or consist of IL-4R or a ligand-binding portion thereof.
• Target molecules also include tumor-associated antigens, as described elsewhere herein. pH-DEPENDENT BINDING
• the present invention provides multispecific antigen-binding molecules comprising a first antigen-binding domain (D1 ) and a second antigen-binding domain (D2), wherein one or both of the antigen-binding domains (D1 and/or D2) binds its antigen (T or E) in a pH-dependent manner.
• an antigen-binding domain (D1 and/or D2) may exhibit reduced binding to its antigen at acidic pH as compared to neutral pH.
• an antigen-binding domain (D1 and/or D2) may exhibit enhanced binding to its antigen at acidic pH as compared to neutral pH.
• Antigen-binding domains with pH-dependent binding characteristics may be obtained, e.g., by screening a population of antibodies for reduced (or enhanced) binding to a particular antigen at acidic pH as compared to neutral pH. Additionally, modifications of the antigen- binding domain at the amino acid level may yield antigen-binding domains with pH-dependent characteristics. For example, by substituting one or more amino acid of an antigen-binding domain (e.g., within a CDR) with a histidine residue, an antigen-binding domain with reduced antigen-binding at acidic pH relative to neutral pH may be obtained.
• the present invention includes multispecific antigen-binding molecules comprising a D1 and/or D2 component that binds its respective antigen (T or E) at acidic pH with a K D that is at least about 3, 5, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more times greater than the K D of the D1 and/or D2 component for binding to its respective antigen at neutral pH. pH dependent binding may also be expressed in terms of the t1 ⁇ 2 of the antigen-binding domain for its antigen at acidic pH compared to neutral pH.
• the present invention includes multispecific antigen-binding molecules comprising a D1 and/or D2 component that binds its respective antigen (T or E) at acidic pH with a VA that is at least about 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more times shorter than the t1 ⁇ 2 of the D1 and/or D2 component for binding to its respective antigen at neutral pH.
• a D1 and/or D2 component that binds its respective antigen (T or E) at acidic pH with a VA that is at least about 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more times shorter than the t1 ⁇ 2 of the D1 and/or D2 component for binding to its respective antigen at neutral pH.
• Multispecific antigen-binding molecules of the present invention that comprise a D1 and/or D2 component with reduced antigen binding at acidic pH as compared to neutral pH, when administered to animal subjects, may in certain embodiments exhibit slower clearance from circulation as compared to comparable molecules that do not exhibit pH-dependent binding characteristics.
• multispecific antigen-binding molecules with reduced antigen binding to either T and/or E at acidic pH as compared to neutral pH are provided which exhibit at least 2 times slower clearance from circulation relative to comparable antigen-binding molecules that do not possess reduced antigen binding at acidic pH as compared to neutral pH. Clearance rate can be expressed in terms of the half-life of the antibody, wherein a slower clearance correlates with a longer half-life.
• the expression “acidic pH” means a pH of 6.0 or less.
• the expression “acidic pH” includes pH values of about 6.0, 5.95, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1 , 5.05, 5.0, or less.
• the expression “neutral pH” means a pH of about 7.0 to about 7.4.
• the expression “neutral pH” includes pH values of about 7.0, 7.05, 7.1 , 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
• T target molecule
• E internalizing effector protein
• the expression "attenuates the activity of T to a greater extent than the binding of T by D1 alone” means that, in an assay in which the activity of T can be measured using cells that express E, the level of T activity measured in the presence of a multispecific antigen-binding molecule is at least 10% lower than the level of T activity measured in the presence of a control construct containing D1 by itself (i.e., not physically linked to the second antigen-binding domain (D2)).
• the level of T activity measured in the presence of the multispecific antigen- binding molecule may be about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the level of T activity measured in the presence of a control construct containing D1 by itself.
• Example 1 A non-limiting, illustrative assay format for determining whether a multispecific antigen- binding molecule attenuates the activity of a target molecule to a greater extent than the binding of the target molecule by the D1 domain alone is shown in working Examples 1 and 2, herein below.
• T is the interleukin-4 receptor (IL-4R)
• E is CD63.
• the multispecific antigen-binding molecule of Example 1 is a 2-antibody conjugate comprising an anti-I L-4R mAb linked to an anti-CD63 mAb via a streptavidin/biotin linker.
• D1 in this exemplary construct is the antigen-binding domain (HCVR/LCVR pair) of the anti-l L-4R antibody
• D2 is the antigen-binding domain (HCVR/LCVR pair) of the anti-CD63 antibody.
• the amount of I L-4-induced reporter activity detected in the presence of the multispecific antigen- binding molecule was compared to the amount of I L-4-induced reporter activity detected in the presence of control constructs containing the anti-l L-4R antibody either connected to an irrelevant control immunoglobulin (control 1 ), or combined with, but not physically connected to, the anti-CD63 antibody (control 2).
• control constructs thus produce the condition in which T is bound by D1 alone (i.e., wherein D1 is not a part of the multispecific antigen-binding molecule per se).
• the extent of target molecule activity (represented by the reporter signal) observed in the presence of the multispecific antigen-binding molecule is at least 10% less than the amount of target molecule activity observed in the presence of a control construct comprising the D1 component not physically linked to the D2 component (e.g., control 1 or control 2), then for purposes of the present disclosure, it is concluded that "the simultaneous binding of T and E by the multispecific antigen-binding molecule attenuates the activity of T to a greater extent than the binding of T by D1 alone.”
• the binding of T by D1 alone may, in some embodiments, result in partial attenuation of the activity of T (as in the case of Example 1 where the treatment of reporter cells with an anti-l L-4R antibody alone [i.e., controls 1 and 2] caused a small level of attenuation of I L-4 signaling relative to untreated cells).
• the binding of T by D1 alone will result in no detectable attenuation of the activity of T; that is, the biological activity of T may be unaffected by the binding of T by D1 alone.
• the simultaneous binding of T and E by a multispecific antigen-binding molecule of the invention will attenuate the activity of T to a greater extent than the binding of T by D1 alone.
• the multispecific antigen-binding molecules are useful for targeting tumor cells.
• the target molecule "T" to which D1 binds is a tumor-associated antigen.
• the tumor-associated antigen is an antigen that is not ordinarily internalized.
• the internalizing effector protein "E" to which D2 binds may be tumor specific, or it may be expressed on both tumor and non-tumor cells of an individual. Any of the internalizing effector proteins mentioned elsewhere herein may be targeted for anti-tumor applications of the invention.
• tumor-associated antigen includes proteins or polypeptides that are preferentially expressed on the surface of a tumor cell.
• the expression “preferentially expressed,” as used in this context, means that the antigen is expressed on a tumor cell at a level that is at least 10% greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 1 10%, 150%, 200%, 400%, or more) than the expression level of the antigen on non- tumor cells.
• the target molecule is an antigen that is preferentially expressed on the surface of a tumor cell selected from the group consisting of a renal tumor cell, a colon tumor cell, a breast tumor cell, an ovarian tumor cell, a skin tumor cell, a lung tumor cell, a prostate tumor cell, a pancreatic tumor cell, a glioblastoma cell, a head and neck tumor cell and a melanoma cell.
• a tumor cell selected from the group consisting of a renal tumor cell, a colon tumor cell, a breast tumor cell, an ovarian tumor cell, a skin tumor cell, a lung tumor cell, a prostate tumor cell, a pancreatic tumor cell, a glioblastoma cell, a head and neck tumor cell and a melanoma cell.
• Non-limiting examples of specific tumor-associated antigens include, e.g., AFP, ALK, BAGE proteins, ⁇ -catenin, brc-abl, BRCA1 , BORIS, CA9, carbonic anhydrase IX, caspase-8, CD40, CDK4, CEA, CTLA4, cyclin-B1 , CYP1 B1 , EGFR, EGFRvll l, ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EphA2, Fra-1 , FOLR1 , GAGE proteins (e.g., GAGE-1 , -2), GD2, GD3, GloboH, glypican-3, GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, H LA MAG E-A3, hTERT, LMP2, MAGE proteins (e.g., MAGE-1 , -2, -3, -4, -6, and -12), MART-1
• the multispecific antigen-binding molecule may be conjugated to a drug, toxin, radioisotope, or other substance which is detrimental to the viability of a cell.
• the drug or toxin may be a substance which does not directly kill a cell, but renders a cell more susceptible to killing by other external agents.
• the multispecific antigen-binding molecule of the invention is not itself conjugated to a drug, toxin or radioisotope, but instead is administered in combination with a second antigen-binding molecule specific for the target (T) (herein referred to as an "accomplice molecule"), wherein the accomplice molecule is conjugated to a drug, toxin or radioisotope.
• the multispecific antigen binding molecule will preferably bind to an epitope on the target molecule (T) that is distinct from and/or non-overlapping with the epitope recognized by the accomplice molecule (i.e. , to allow for simultaneous binding of the multispecific antigen-binding molecule and the accomplice molecule to the target).
• the present invention also includes anti-tumor combinations, and therapeutic methods, comprising: (a) a toxin- or drug-conjugated antigen-binding molecule that specifically binds a tumor-associated antigen; and (b) a multispecific antigen-binding molecule comprising (i) a first binding domain that specifically binds an internalizing effector protein ⁇ e.g. , with low affinity) and (ii) a second binding domain that specifically binds the toxin- or drug-conjugated antigen-binding molecule.
• the multispecific antigen- binding molecule functions to link the toxin- or drug-conjugated antigen-binding molecule to the internalizing effector protein, which thereby functions to physically link the tumor associated antigen to the internalizing effector protein. Internalization of the toxin-labeled anti-tumor- associated antigen antibody via its connection to the internalizing effector protein would consequently result in targeted tumor cell killing.
• the multispecific antigen-binding molecule may be conjugated to one or more cytotoxic drugs selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis- platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, larotaxel, tesetaxel, orataxel, docetaxel, dolastatin 10, auristatin E, auristatin PHE and maytansine-based compounds (e.g., DM1 , DM4, etc.).
• cytotoxic drugs selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-
• the multispecific antigen-binding molecule may also, or alternatively, be conjugated to a toxin such as diphtheria toxin, Pseudomonas aeruginosa exotoxin A, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins, etc.
• a toxin such as diphtheria toxin, Pseudomonas aeruginosa exotoxin A, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins, etc.
• the multispecific antigen-binding molecule may also, or alternatively, be conjugated to one or more radioisotope selected from the group consisting of 225 Ac, 211 At, 212 Bi, 213 Bi, 186 Rh, 188 Rh, 177 Lu, 90 Y, 13 , 67 Cu, 125 l, 123 l , 77 Br, 153 Sm, 166 Ho, 64 Cu, 121 Pb, 224 Ra and 223 Ra.
• this aspect of the invention includes multispecific antigen-binding molecules that are antibody-drug conjugates (ADCs) or antibody-radioisotope conjugates (ARCs).
• the D2 component may, in certain circumstances, bind with low affinity to the internalizing effector protein "E".
• the multispecific antigen-binding molecule will preferentially target tumor cells that express the tumor-associated antigen.
• "low affinity" binding means that the binding affinity of the D2 component for the internalizing effector protein (E) is at least 10% weaker ⁇ e.g. , 15% weaker, 25% weaker, 50% weaker, 75% weaker, 90% weaker, etc.) than the binding affinity of the D1 component for the target molecule (T).
• low affinity binding means that the D2 component interacts with the internalizing effector protein (E) with a K D of greater than about 10 nM to about 1 ⁇ , as measured in a surface plasmon resonance assay at about 25°C.
• the simultaneous binding of a multispecific antigen-binding molecule to an internalizing effector protein and a tumor-associated antigen will result in preferential internalization of the multispecific antigen-binding molecule into tumor cells.
• the multispecific antigen-binding molecule is conjugated to a drug, toxin or radioisotope (or if the multispecific antigen-binding molecule is administered in combination with an accomplice antibody that is conjugated to a drug, toxin or radioisotope)
• the targeted internalization of the tumor-associated antigen into the tumor cell via its linkage to the multispecific antigen-binding molecule will result in extremely specific tumor cell killing.
• the present invention includes pharmaceutical compositions comprising a multispecific antigen-binding molecule.
• the pharmaceutical compositions of the invention can be formulated with suitable carriers, excipients, and other agents that provide improved transfer, delivery, tolerance, and the like.
• the present invention also includes methods for inactivating or attenuating the activity of a target molecule (T).
• the methods of the present invention comprise contacting a target molecule with a multispecific antigen-binding molecule as described herein.
• the methods according to this aspect of the invention comprise administering a pharmaceutical composition comprising a multispecific antigen-binding molecule to a patient for whom it is desirable and/or beneficial to inactivate, attenuate, or otherwise decrease the extracellular concentration of a target molecule.
• compositions of the present invention can be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g. , oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other biologically active agents. Administration can be systemic or local.
• a pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe.
• a pen delivery device can be used to administer a pharmaceutical composition of the present invention to a patient.
• a multispecific antigen-binding molecule was created which is capable of binding (a) an internalizing effector molecule and (b) a cell surface receptor target molecule.
• the internalizing effector protein is Kremen-2 (Krm2)
• the cell surface receptor target molecule is an Fc receptor (FcyR1 [Fc-gamma-R1]).
• Kremen molecules are cell-surface proteins known to mediate WNT signaling by directing the internalization and degradation of the WNT pathway signaling molecules LRP5 and LRP6. Internalization of LRP5/6 is accomplished via the soluble interacting protein DKK1. In particular, DKK1 links Kremen to LRP5/6 on the cell surface, and because of this linkage, the internalization of Kremen drives the internalization and degradation of LRP5 and LRP6. (See Li ei a/., PLoS One 5(6):e11014).
• a multispecific antigen-binding molecule was constructed consisting of DKK1 fused to a mouse Fc (DKK1-mFc, having the amino acid sequence of SEQ ID NO:1 ).
• DKK1-mFc mouse Fc
• a multispecific antigen-binding molecule is defined as a molecule comprising a first antigen-binding domain (D1 ) which specifically binds a target molecule, and a second antigen-binding domain (D2) which specifically binds an internalizing effector protein.
• the "first antigen-binding domain” is the mFc component which specifically binds the target molecule FcyR1
• the "second antigen-binding domain” is the DKK1 component which specifically binds the internalizing effector protein Kremen.
• FcyR1 immunoprecipitation mouse anti-FcyR1 antibody was added to cell lysates and incubated for 1 hour at 4°C. Then Protein-G beads were added and the mixture was incubated for 1 hour at 4°C. The beads were then washed and the proteins eluted and subjected to SDS-PAGE.
• Proteins were transferred to membrane and probed with HRP-labeled streptavidin to reveal relative amounts of remaining surface-exposed FcyR1 protein in each sample. Results are shown in Figure 2.
• Example 2 IL-4R Activity is Attenuated Using a Multispecific Antigen-Binding Molecule with Specificity for IL-4R and CD63
• a multispecific antigen-binding molecule was constructed which is capable of simultaneously binding a cell surface-expressed target molecule ⁇ i.e., IL-4R) and a cell surface-expressed internalizing effector protein (i.e., CD63).
• the purpose of these experiments was to determine whether IL-4R activity on a cell can be attenuated to a greater extent by physically linking IL-4R to an effector molecule that is internalized and targeted for degradation within the lysosome (in this case, CD63).
• this Example was designed to test whether the normal internalization and degradation of CD63 could be used to force the internalization and degradative rerouting of IL-4R within a cell.
• a multispecific antigen-binding molecule was constructed that is able to bind both IL-4R and CD63.
• a streptavidin-conjugated anti-IL-4R antibody and a biotinylated anti-CD63 antibody were combined in a 1 :1 ratio to produce an anti-IL-4R:anti-CD63 conjugate (i.e., a multispecific antigen-binding molecule that specifically binds both IL-4R and CD63).
• the anti-IL-4R antibody used in this Example is a fully human mAb raised against the IL-4R extracellular domain.
• the anti-IL-4R antibody comprised a heavy chain variable region having SEQ ID NO:3 and a light chain variable region having SEQ ID NO:4).
• the anti-CD63 antibody used in this Example is the mouse anti-human CD63 mAb clone MEM-259, obtained from Biolegend (San Diego, CA), catalog. No. 312002.
• Control-1 streptavidin-conjugated anti-IL- 4R antibody combined in a 1 :1 ratio with biotinylated control mouse lgG1 kappa antibody
• Control-2 streptavidin-conjugated anti-IL-4R antibody combined in a 1 :1 ratio with non- biotinylated anti-CD63 antibody.
• the anti-IL-4R antibody used in the experimental and control constructs for this Example is an antibody that is known to specifically bind IL-4R and only partially block IL-4-mediated signaling.
• the experimental cell line used in this Example is an HEK293 cell line containing a STAT6-luciferase reporter construct and additional STAT6 ("HEK293/STAT6-luc cells").
• the cells used in this experiment express both IL-4R and CD63 on their surface. When treated with IL-4 in the absence of any inhibitors, this cell line produces a dose-dependent detectable chemiluminescence signal which reflects the extent of IL-4-mediated signaling.
• HEK293/STAT6-luc reporter cell line for various amounts of time prior to the addition of IL-4.
• the molecules were allowed to incubate with the reporter cell line for 0 hours (i.e., added concurrently with IL-4), 2 hours, or overnight prior to the addition of 50 pM IL-4. Luciferase activity was measured six hours after the addition of IL-4. Results are shown in Figure 5, top panel ("untransfected").
• a similar protocol was carried out, except that the experimental or control molecules were allowed to incubate with the reporter cell line for 15 minutes, 30 minutes, 1 hour or 2 hours prior to the addition of 50 pM IL-4. Results are shown in Figure 6.
• this Example provides further proof-of-concept for the inhibition of a target molecule activity through the use of a multispecific antigen-binding molecule that is capable of simultaneously binding both the target molecule (in this case IL-4R) and an internalizing effector protein (in this case CD63) to thereby cause the internalization and degradative rerouting of the target molecule within a cell.
• a multispecific antigen-binding molecule that is capable of simultaneously binding both the target molecule (in this case IL-4R) and an internalizing effector protein (in this case CD63) to thereby cause the internalization and degradative rerouting of the target molecule within a cell.
• the simultaneous binding of IL-4R and CD63 by the exemplary multispecific antigen-binding molecule attenuated the activity of IL-4R to a substantially greater extent (i.e., > 10%) than the binding of IL-4R by the control constructs alone.
• Example 2 shows that an anti-IL-4R/anti-CD63 multispecific molecule inhibits IL-4-mediated signaling in a CD63-dependent manner.
• the multispecific antigen-binding molecule consisted of two separate monoclonal antibodies (anti-IL-4R and anti-CD63) that were connected via a biotin-streptavidin linkage.
• a true bispecific antibody was constructed.
• Standard bispecific antibody technology was used to construct a bispecific antibody consisting of a first arm specific for IL-4R and a second arm specific for CD63.
• the IL-4R- specific arm contained an anti-IL-4R heavy chain paired with a CD63-specific light chain.
• the CD63-specific light chain was paired with the IL-4R specific heavy chain solely for purposes of convenience of construction; nevertheless, the pairing of the anti-IL-4R heavy chain with the anti-CD63 light chain retained full specificity for IL-4R and did not exhibit binding to CD63.
• the CD63-specific arm contained an anti-CD63 heavy chain paired with an anti-CD63 light chain (the same light chain as used in the IL-4R arm).
• the anti-IL-4R heavy chain (comprising SEQ ID NO:3) was derived from the full anti-IL-4R antibody as used in Example 2; However, the anti- CD63 heavy and light chains were derived from the anti-CD63 antibody designated H5C6, obtained from the Developmental Studies Hybridoma Bank (University of Iowa Department of Biology, Iowa City, IA). As with the full anti-IL-4R antibody used in Example 2, the anti-IL-4R component of the bispecific antibody used in this Example exhibited only moderate IL-4R blocking activity on its own.
• An IL-4 luciferase assay was carried out to assess the blocking activity of the anti-IL- 4R x anti-CD63 bispecific antibody. Briefly, serial dilutions of anti-I L-4R x anti-CD63 bispecific antibody or control molecules were added to HEK293/STAT6-luc reporter cells (see Example 2). Under normal conditions, these cells produce a detectable luciferase signal when treated with I L-4. For this experiment, 10 pM IL-4 was then added to the cells, and luciferase activity was quantified for each dilution of antibody used.
• the controls used in this assay were: (a) mock bispecific antibody that binds IL-4R with one arm and has a non-functional anti-CD63 arm (i.e. , containing one anti-I L-4R heavy chain and one anti-CD63 heavy chain, both paired with the anti-IL-4R light chain); (b) anti-I L-4R monospecific antibody; and (c) buffer (PBS) only (without antibody). Results are shown in Figure 7. As shown in Figure 7, for the control samples used, luciferase activity remained relatively high even at the highest antibody concentrations, whereas for the bispecific antibody, luciferase activity declined significantly as antibody concentration increased. These results confirm that simultaneous binding of IL-4R and CD63 by a bispecific antibody causes substantial inhibition of IL-4R activity.
• the ability of multispecific antigen-binding molecules to promote the internalization of the soluble target molecule SOST was assessed.
• the target molecule was a fusion protein consisting of a human SOST protein tagged with a pHrodoTM moiety (Life Technologies, Carlsbad, CA) and a myc tag.
• the pHrodoTM moiety is a pH-sensitive dye that is virtually non-fluorescent at neutral pH and brightly fluorescent in an acidic environment such as the endosome. The fluorescent signal, therefore, can be used as an indicator of cellular internalization of the SOST fusion protein.
• the multispecific antigen-binding molecules for these experiments were bispecific antibodies with binding specificity for both CD63 (an internalizing effector protein) and the SOST fusion protein (a soluble target molecule), as described in more detail below.
• HEK293 cells were plated at 10,000 cells/well in poly-D-lysine coated 96 well plates (Greiner Bio-One, Monroe, NC). After allowing the cells to settle overnight, the media was replaced with media containing antibody (5 ⁇ g/mL, as described below), pHrodoTM-myc-tagged-SOST (5 ⁇ g/mL), heparin (10 ⁇ 9/ ⁇ _), and Hoechst 33342. The cells were then incubated for either 3 hours on ice or 3 hours at 37°C.
• anti-CD63 monospecific antibody clone H5C6, Developmental Studies Hybridoma Bank, University of Iowa Department of Biology, Iowa City, IA
• anti-myc antibody clone 9E10, Schiweck et al., 1997, FEBS Lett. 414(1 ):33-38
• anti-SOST antibody an antibody having the heavy and light chain variable regions of the antibody designated "Ab-B" in US Patent No. 7,592,429
• anti-CD63 x anti- myc bispecific antibody i.e.
• a multispecific antigen-binding molecule comprising an anti-CD63 arm derived from the antibody H5C6 and an anti-myc arm derived from 9E10); (5) anti-CD63 x anti-SOST bispecific antibody #1 (i.e., a multispecific antigen-binding molecule comprising an anti-CD63 arm derived from the antibody H5C6 and an anti-SOST arm derived from "Ab-B”); and (6) anti-CD63 x anti-SOST bispecific antibody #2 (i.e., a multispecific antigen-binding molecule comprising an anti-CD63 arm derived from the antibody H5C6 and an anti-SOST arm derived from the antibody designated "Ab-20" in US Patent No. 7,592,429).
• the bispecific antibodies used in these experiments were assembled using the so-called "knobs-into-holes" methodology (see, e.g., Ridgway et al., 1996, Protein Eng. 9(7):617-621 ).
• FIG. 8 shows the number of spots (labeled vesicles) per cell, under the various treatment conditions tested.
• the results of these experiments demonstrate that the bispecific constructs, which simultaneously bind CD63 and SOST (either directly or via the myc tag), caused the greatest amount of SOST internalization as reflected by the fluorescence intensity and number of fluorescent spots per cell over time at 37°C.
• the multispecific antigen-binding molecules used in this Example are able to effectively direct the internalization of a soluble target molecule.
• mice An anti-CD63 x anti-SOST multispecific antigen-binding molecule, as described in Example 4, is next tested for its ability to increase bone mineral density in mice.
• Five groups of mice are used in these experiments.
• the treatment groups are as follows: (I) untreated negative control mice; (II) mice treated with a blocking anti-SOST monospecific antibody that is known to increase bone mineral density on its own (positive control); (I II) mice treated with a bispecific antibody that specifically binds CD63 and SOST but does not inhibit SOST activity on its own or only slightly inhibits SOST activity on its own; (IV) mice treated with an anti-CD63 parental antibody (i.e., a monospecific antibody containing the same anti-CD63 antigen-binding domain as in the bispecific antibody); and (V) mice treated with an anti-SOST parental antibody (i.e. , a monospecific antibody containing the same anti-SOST antigen-binding domain as in the bispecific antibody).
• mice in group I II (treated with an anti-SOST x anti-CD63 bispecific antibody) will exhibit an increase in bone mineral density that is at least comparable to that which is observed in the mice of group II (treated with a known blocking anti-SOST antibody), even though the anti-SOST component of the bispecific antibody does not inhibit SOST activity on its own (as confirmed by the mice in Group V which are expected to not exhibit an increase in bone mineral density).
• the increase in bone mineral density that is expected in the mice of group III is believed to be driven by CD63-mediated internalization of SOST, as observed in the cellular experiments of Example 4, above.
• This Example illustrates the use of a multispecific antigen-binding molecule of the invention to direct the internalization of a non-protein target molecule, namely lipopolysaccharide (LPS).
• LPS is a component of the outer membrane of Gram-negative bacteria and is known to contribute to septic shock.
• Anti-LPS antibodies have been investigated as possible treatment agents for sepsis. The experiments of the present Example were designed to assess the ability of a multispecific antigen-binding molecule to promote the internalization of LPS.
• the multispecific antigen-binding molecule used in this Example was a bispecific antibody with one arm directed to LPS (target) and the other arm directed to CD63 (internalizing effector protein).
• the anti-LPS arm was derived from the antibody known as WN1 222-5.
• the anti-CD63 arm was derived from the H5C6 antibody (see Example 4).
• the anti-LPS x anti-CD63 bispecific antibody i.e., multispecific antigen- binding molecule
• was assembled using the so-called "knobs-into-holes" methodology see, e.g., Ridgway et al., 1996, Protein Eng. 9(7):617-621 ).
• LPS species Two LPS species were used in these experiments: E. coli LPS and Salmonella minnesota LPS. Both versions were obtained as fluorescent-labeled molecules (ALEXA- FLUOR®-488-labeled LPS, Life Technologies, Carlsbad, CA).
• HEK293 cells were plated in 96-well PDL- coated imaging plates. After overnight rest, media was replaced with fresh medium. Fluorescently labeled LPS (either E. coli- or S. m/nnesoia-derived) was added in regular medium. Next, the anti-LPS x anti-CD63 bispecific antibody, or control half-antibodies paired with dummy Fc, were added to the samples. Following various incubation times at 37°C (1 hour and 3 hours) or on ice (3 hours), cells from the LPS-treated samples were processed as follows: washed - quenched with anti- ALEXA-FLUOR®-488 antibody - washed & fixed.
• the anti- ALEXA-FLUOR®-488 antibody quenches fluorescence from non-internalized (i.e., surface bound) fluorophore.
• any fluorescence observed in the quenching antibody-treated samples is due to internalized LPS.
• the level of fluorescence from each sample at the various time points was measured.
• Figure 9 expresses the results of these experiments in terms of the number of labeled vesicles per cell. As shown in Figure 9, only cells treated with the anti-CD63 x anti-LPS bispecific antibody demonstrated significant numbers of labeled vesicles that increased over time. Cells treated with labeled LPS and the control antibodies did not exhibit appreciable numbers of fluorescent vesicles, indicating that LPS was not internalized under those treatment conditions.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Toxicology (AREA)
• Rheumatology (AREA)
• Cell Biology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Endocrinology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (21)

Applications Claiming Priority (6)

Publications (1)

Family

ID=48014317

Family Applications (1)

Country Status (19)

Cited By (29)

Families Citing this family (33)

Citations (4)

Family Cites Families (76)

• 2013
  • 2013-03-13 BR BR112014022692A patent/BR112014022692A8/pt not_active Application Discontinuation
  • 2013-03-13 KR KR1020207017530A patent/KR102283200B1/ko active Active
  • 2013-03-13 SG SG11201405468QA patent/SG11201405468QA/en unknown
  • 2013-03-13 SG SG10201704846VA patent/SG10201704846VA/en unknown
  • 2013-03-13 PL PL13712987T patent/PL2825553T3/pl unknown
  • 2013-03-13 KR KR1020217023450A patent/KR102494534B1/ko active Active
  • 2013-03-13 AU AU2013232266A patent/AU2013232266A1/en not_active Abandoned
  • 2013-03-13 ES ES13712987.0T patent/ES2687974T3/es active Active
  • 2013-03-13 KR KR20147027652A patent/KR20140135233A/ko not_active Ceased
  • 2013-03-13 CN CN201380020750.9A patent/CN104302664B/zh active Active
  • 2013-03-13 NZ NZ631565A patent/NZ631565A/en unknown
  • 2013-03-13 EP EP13712987.0A patent/EP2825553B1/en active Active
  • 2013-03-13 MY MYPI2018703207A patent/MY198567A/en unknown
  • 2013-03-13 US US13/798,205 patent/US20130243775A1/en not_active Abandoned
  • 2013-03-13 CA CA2867265A patent/CA2867265C/en active Active
  • 2013-03-13 WO PCT/US2013/030636 patent/WO2013138400A1/en not_active Ceased
  • 2013-03-13 MY MYPI2014002545A patent/MY171761A/en unknown
  • 2013-03-13 JP JP2015500534A patent/JP6883944B2/ja active Active
  • 2013-03-13 SG SG10201709018QA patent/SG10201709018QA/en unknown
  • 2013-03-13 EA EA201491686A patent/EA036225B1/ru not_active IP Right Cessation
  • 2013-03-13 EP EP18172145.7A patent/EP3421488A3/en not_active Withdrawn
  • 2013-03-13 CN CN202111438717.0A patent/CN114133454A/zh active Pending
  • 2013-03-13 MX MX2014011052A patent/MX361875B/es active IP Right Grant
  • 2013-03-13 DK DK13712987.0T patent/DK2825553T3/en active
• 2014
  • 2014-09-04 IL IL23446014A patent/IL234460B/en active IP Right Grant
  • 2014-09-11 ZA ZA2014/06671A patent/ZA201406671B/en unknown
  • 2014-09-12 MX MX2022012083A patent/MX2022012083A/es unknown
  • 2014-09-12 MX MX2018010776A patent/MX2018010776A/es unknown
• 2017
  • 2017-10-27 AU AU2017251854A patent/AU2017251854B2/en active Active
• 2018
  • 2018-04-03 JP JP2018071539A patent/JP2018168152A/ja not_active Withdrawn
• 2019
  • 2019-02-01 JP JP2019016596A patent/JP7308041B2/ja active Active
  • 2019-04-25 US US16/394,849 patent/US11578135B2/en active Active
• 2022
  • 2022-01-24 JP JP2022008369A patent/JP7579291B2/ja active Active

Patent Citations (4)

Also Published As

Similar Documents

Legal Events